Holistic Integrative Oncology（HIO，eISSN:2731-4529; CN12-1481/R73）是由中国抗癌协会与Springer Nature出版集团于2021年强强联合打造的一本英文大刊，主编为中国抗癌协会理事长樊代明院士。HIO入选了2022年中国科技期刊卓越行动计划高起点新刊项目，是面向全球开放的自由获取同行评议期刊，设有CACA指南、专家述评、研究综述和原创论著等栏目。男性生殖系统肿瘤专题文章已正式上线，敬请各位读者阅读、引用与分享！
本专题目录
01 CACA guidelines for holistic integrative management of prostate cancer
文章类型：Guideline
引用格式：Dai, B., Wang, H., Shi, B. et al. CACA guidelines for holistic integrative management of prostate cancer. Holist Integ Oncol 3, 47 (2024). https://doi.org/10.1007/s44178-024-00118-4
扫描上方二维码，进入详细阅读
02 Review of management of primary oesophagogastric cancers in East Asian versus Western countries
文章类型：Commentary
引用格式：Chaganti, R., Wong, M. Review of management of primary oesophagogastric cancers in East Asian versus Western countries. Holist Integ Oncol 3, 38 (2024). https://doi.org/10.1007/s44178-024-00108-6
扫描上方二维码，进入详细阅读
03 Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis
文章类型：Review
引用格式：Tian, Y., Liu, Z., Mulati, Y. et al. Clinical efficacy of current treatments for high-volume metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Holist Integ Oncol 3, 39 (2024).https://doi.org/10.1007/s44178-024-00106-8
扫描上方二维码，进入详细阅读
04 A boost or a redundancy? on the value of combination of androgen receptor signal inhibitor and PARP inhibitor for advanced prostate cancer
文章类型：Review
引用格式：Wang, Q., Ye, J., Zheng, L. et al. A boost or a redundancy? on the value of combination of androgen receptor signal inhibitor and PARP inhibitor for advanced prostate cancer. Holist Integ Oncol 3, 46 (2024).https://doi.org/10.1007/s44178-024-00119-3
扫描上方二维码，进入详细阅读
05 A comprehensive analysis and comparison of lipid metabolism and inflammatory indices in patients with benign prostatic hyperplasia and prostate cancer
文章类型：Original Research
引用格式：Xu, L., Xu, Y., Chen, S. et al. A comprehensive analysis and comparison of lipid metabolism and inflammatory indices in patients with benign prostatic hyperplasia and prostate cancer. Holist Integ Oncol 3, 37 (2024). https://doi.org/10.1007/s44178-024-00105-9
扫描上方二维码，进入详细阅读
06 Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer
文章类型：Short Communication
引用格式：Qi, F., Xu, Y., Xu, Z. et al. Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer. Holist Integ Oncol 4, 3 (2025). https://doi.org/10.1007/s44178-024-00146-0
扫描上方二维码，进入详细阅读
